$3.36
-0.23-6.41%
마지막 업데이트: Oct 16, 7:25 PM
$3.37
-0.22-6.08%
Benzinga
Benzinga
Benzinga
토요일, 10월 17
Benzinga
© 2026 Benzinga | All Rights Reserved
Unicycive Therapeutics (UNCY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.33 | $-0.49 | $-0.46 | $-0.55 |
| Actual | $-0.06 | $-0.54 | $-0.82 | $-0.46 |
| Surprise | +81.8% | -10.2% | -78.3% | +16.4% |
| Revenue | ||||
| Estimate | $28.6M | $14.3M | $590860 | $265620 |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | -100.0% | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.35 | $-0.32 | $0.22 | $0.32 |
| Revenue | ||||
| Consensus | $1.2M | $393336 | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.06 | $-0.33 | 81.8 % |
| Q1 | May 12, 2026 | $-0.54 | $-0.49 | -10.2 % |
| Q4 | Mar 30, 2026 | $-0.82 | $-0.46 | -78.3 % |
| Q3 | Nov 12, 2025 | $-0.46 | $-0.55 | 16.4 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $0 | $28.57M | -100.0 % |
| Q1 | May 12, 2026 | $0 | $14.29M | -100.0 % |
| Q4 | Mar 30, 2026 | $0 | $590.86K | -100.0 % |
| Q3 | Nov 12, 2025 | $0 | $265.62K | -100.0 % |